QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Makela, E. H Articles by Gunel, E. Search for Related Content PubMed PubMed Citation Articles by Makela, E. H Articles by Gunel, E.

PSYCHIATRY

Branded versus Generic Clozapine for Treatment of Schizophrenia

Associate Professor, Schools of Pharmacy and Medicine, West Virginia University, Morgantown, WV

William D Cutlip, II, MD

Associate Professor, School of Medicine, West Virginia University

James M Stevenson, MD

Professor, School of Medicine, West Virginia University

Jason M Weimer, BS

Program Coordinator, Thought Disorders Program, School of Medicine, West Virginia University

Ehab S Abdallah, MD

Resident, Department of Behavioral Medicine and Psychiatry, West Virginia University

Raja S Akhtar, MBBS MPH

at time of writing, Department of Community Medicine, West Virginia University; now, West Virginia State Health Department

Ahmed S Aboraya, MD DrPH

Assistant Professor, School of Medicine, West Virginia University

Erdogan Gunel, PhD

Professor, College of Arts and Sciences, West Virginia University

Reprints: Eugene H Makela PharmD BCPP, Schools of Pharmacy and Medicine, West Virginia University, PO Box 9520, Morgantown, WV 26506-9520, FAX 304/293-7672, E-mail gmakela{at}hsc.wvu.edu

OBJECTIVE: To report clinical findings resulting from a switch from branded to generic clozapine.

METHODS: Twenty patients diagnosed with schizophrenia were followed in this naturalistic outpatient study. The Positive and Negative Syndrome Scale (PANSS), Beck Anxiety Inventory (BAI), Abnormal Involuntary Movement Scale, and the Movement Disorder Assessment were used to assess differences in the clinical status of patients before and after switching from Clozaril to generic clozapine (Mylan Pharmaceuticals). Results were analyzed by means of the paired t-test and by calculation of the percent change in mean scores. A clinically significant change as measured by the PANSS was defined as a ± 20% change in mean scores at final evaluation. The design was open-label and non-blinded.

RESULTS: At the final evaluation, the t-test revealed no significant differences between branded and generic clozapine for the total PANSS, the positive symptom, negative symptom, and the general psychopathology subscales of the PANSS, and the BAI. There were no clinically significant changes for any measure.

CONCLUSIONS: In this small group of patients with schizophrenia, no deterioration in clinical status in several domains was noted after changing from branded to generic clozapine. This finding is consistent with pharmacologic data suggesting bioequivalence of the 2 products. Results, however, must be interpreted cautiously due to the lack of optimal study controls and small sample size.

Key Words: clozapine, Clozaril, switch

Published Online, January 27, 2003. www.theannals.com, DOI 10.1345/aph.1C069

This article has been cited by other articles:

				M. Van Ameringen, C. Mancini, B. Patterson, and M. Bennett Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series J Psychopharmacol, July 1, 2007; 21(5): 472 - 476. [Abstract] [PDF]

				C. Paton Generic clozapine: outcomes after switching formulations The British Journal of Psychiatry, August 1, 2006; 189(2): 184 - 185. [Abstract] [Full Text] [PDF]